{"id":473675,"date":"2021-04-08T09:14:49","date_gmt":"2021-04-08T13:14:49","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=473675"},"modified":"2021-04-08T09:14:49","modified_gmt":"2021-04-08T13:14:49","slug":"cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/","title":{"rendered":"CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>\n          <i>Marks vaccine&#8217;s first approval in <span class=\"xn-location\">South America<\/span>, following <span class=\"xn-location\">Mexico<\/span>, <span class=\"xn-location\">Pakistan<\/span>, <span class=\"xn-location\">China<\/span> and <span class=\"xn-location\">Hungary<\/span><\/i>\n        <\/li>\n<li>\n          <i>Safe, stable storage and transportation between 2\u00b0C and 8\u00b0C, accessible by under-developed regions<\/i>\n        <\/li>\n<li>\n          <i>95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination<\/i>\n        <\/li>\n<\/ul>\n<p>\n        <span class=\"xn-location\">TIANJIN, China<\/span>, <span class=\"xn-chron\">April 8, 2021<\/span> \/PRNewswire\/ &#8212; CanSino Biologics Inc. (&#8220;CanSinoBIO&#8221;) (HKEX: 06185) today announced that the Instituto\u00a0de\u00a0Salud\u00a0P\u00fablica\u00a0de\u00a0Chile\u00a0(&#8220;ISP&#8221;) granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (&#8220;Ad5-nCoV&#8221;, trade name: Convidecia\u2122). This marks the first approval of Convidecia\u2122 in <span class=\"xn-location\">South America<\/span> and the first single-dose COVID-19 vaccine approved for emergency use in <span class=\"xn-location\">Chile<\/span>.<\/p>\n<p>On <span class=\"xn-chron\">February 25, 2021<\/span>, Convidecia\u2122 was granted a conditional marketing authorization by the National Medical Products Administration of <span class=\"xn-location\">China<\/span> (&#8220;NMPA&#8221;), the first of its kind authorized in <span class=\"xn-location\">China<\/span>. Globally, Convidecia\u2122 received authorization for emergency use by the Hungarian National Institute of Pharmacy and Nutrition (OGY\u00c9I) in <span class=\"xn-chron\">March 2021<\/span>, and by the Federal Commission for Protection against Sanitary Risks of <span class=\"xn-location\">Mexico<\/span> and the Drug Regulatory Authority of <span class=\"xn-location\">Pakistan<\/span> for adults aged 18 and above in <span class=\"xn-chron\">February 2021<\/span>. <\/p>\n<p>In addition, on <span class=\"xn-chron\">March 22, 2021<\/span>, the NMPA granted approval of CanSinoBIO&#8217;s clinical trial application for an inhaled version of COVID-19 vaccine, marking an important step forward in the Company&#8217;s global fight against the COVID-19 pandemic as the virus continues to evolve.<\/p>\n<p>The interim analysis data of the phase III clinical trial of Convidecia\u2122 shows that Convidecia\u2122 has an overall efficacy of 65.28% at preventing all symptomatic COVID-19 disease 28 days after single dose vaccination, and 68.83% at preventing all symptomatic COVID-19 disease 14 days after single dose vaccination. Convidecia\u2122 has an efficacy of 90.07% at preventing severe disease 28 days after single dose vaccination, and 95.47% at preventing severe disease 14 days after single dose vaccination.<\/p>\n<p>\n        <b>About CanSinoBIO<\/b>\n      <\/p>\n<p>Incorporated in 2009, CanSinoBIO (SHSE: 688185, HKEX: 06185) commits to research, production and commercialization of innovative vaccines for <span class=\"xn-location\">China<\/span> and global public health security. It possesses four integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination and formulation. As of today, it has established a robust pipeline of 16 vaccines preventing 13 diseases, including a globally innovative Ebola virus vaccine (Adenovirus Type 5 Vector) approved in 2017 as well as the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) conditionally approved in 2021. Additional information can be found online at <a href=\"http:\/\/www.cansinotech.com\" rel=\"nofollow\">www.cansinotech.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN36480&amp;sd=2021-04-08\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile-301265147.html\">http:\/\/www.prnewswire.com\/news-releases\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile-301265147.html<\/a><\/p>\n<p>SOURCE  CanSino Biologics Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CN36480&amp;Transmission_Id=202104080911PR_NEWS_USPR_____CN36480&amp;DateId=20210408\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Marks vaccine&#8217;s first approval in South America, following Mexico, Pakistan, China and Hungary Safe, stable storage and transportation between 2\u00b0C and 8\u00b0C, accessible by under-developed regions 95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination TIANJIN, China, April 8, 2021 \/PRNewswire\/ &#8212; CanSino Biologics Inc. (&#8220;CanSinoBIO&#8221;) (HKEX: 06185) today announced that the Instituto\u00a0de\u00a0Salud\u00a0P\u00fablica\u00a0de\u00a0Chile\u00a0(&#8220;ISP&#8221;) granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (&#8220;Ad5-nCoV&#8221;, trade name: Convidecia\u2122). This marks the first approval of Convidecia\u2122 in South America and the first single-dose COVID-19 vaccine approved for emergency use in Chile. On February 25, 2021, Convidecia\u2122 was granted a conditional marketing authorization by the National Medical Products Administration of China (&#8220;NMPA&#8221;), the first &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-473675","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Marks vaccine&#8217;s first approval in South America, following Mexico, Pakistan, China and Hungary Safe, stable storage and transportation between 2\u00b0C and 8\u00b0C, accessible by under-developed regions 95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination TIANJIN, China, April 8, 2021 \/PRNewswire\/ &#8212; CanSino Biologics Inc. (&#8220;CanSinoBIO&#8221;) (HKEX: 06185) today announced that the Instituto\u00a0de\u00a0Salud\u00a0P\u00fablica\u00a0de\u00a0Chile\u00a0(&#8220;ISP&#8221;) granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (&#8220;Ad5-nCoV&#8221;, trade name: Convidecia\u2122). This marks the first approval of Convidecia\u2122 in South America and the first single-dose COVID-19 vaccine approved for emergency use in Chile. On February 25, 2021, Convidecia\u2122 was granted a conditional marketing authorization by the National Medical Products Administration of China (&#8220;NMPA&#8221;), the first &hellip; Continue reading &quot;CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-08T13:14:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN36480&amp;sd=2021-04-08\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile\",\"datePublished\":\"2021-04-08T13:14:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\\\/\"},\"wordCount\":393,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN36480&amp;sd=2021-04-08\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\\\/\",\"name\":\"CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN36480&amp;sd=2021-04-08\",\"datePublished\":\"2021-04-08T13:14:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN36480&amp;sd=2021-04-08\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN36480&amp;sd=2021-04-08\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/","og_locale":"en_US","og_type":"article","og_title":"CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile - Market Newsdesk","og_description":"PR Newswire Marks vaccine&#8217;s first approval in South America, following Mexico, Pakistan, China and Hungary Safe, stable storage and transportation between 2\u00b0C and 8\u00b0C, accessible by under-developed regions 95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination TIANJIN, China, April 8, 2021 \/PRNewswire\/ &#8212; CanSino Biologics Inc. (&#8220;CanSinoBIO&#8221;) (HKEX: 06185) today announced that the Instituto\u00a0de\u00a0Salud\u00a0P\u00fablica\u00a0de\u00a0Chile\u00a0(&#8220;ISP&#8221;) granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (&#8220;Ad5-nCoV&#8221;, trade name: Convidecia\u2122). This marks the first approval of Convidecia\u2122 in South America and the first single-dose COVID-19 vaccine approved for emergency use in Chile. On February 25, 2021, Convidecia\u2122 was granted a conditional marketing authorization by the National Medical Products Administration of China (&#8220;NMPA&#8221;), the first &hellip; Continue reading \"CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-08T13:14:49+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN36480&amp;sd=2021-04-08","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile","datePublished":"2021-04-08T13:14:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/"},"wordCount":393,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN36480&amp;sd=2021-04-08","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/","name":"CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN36480&amp;sd=2021-04-08","datePublished":"2021-04-08T13:14:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN36480&amp;sd=2021-04-08","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN36480&amp;sd=2021-04-08"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-chile\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473675","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=473675"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473675\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=473675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=473675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=473675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}